Delving into the Latest Updates on Blinatumomab with Synapse

Overview

Basic Info

Drug Type

Bispecific T-cell Engager (BiTE)

Synonyms

Blinatumomab (Genetical Recombination), Blinatumomab (genetical recombination) (JAN), Blinatumomab (USAN/INN)

+ [13]

Target

CD19 x CD3

Action

inhibitors, stimulants

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia+ [45]

Inactive Indication

Aggressive B-Cell Non-Hodgkin LymphomaBezoarsCD19 positive Diffuse Large B-Cell Lymphoma+ [6]

Originator Organization

Amgen, Inc.

Active Organization

Amgen, Inc.

National Cancer InstituteAmgen Australia Pty Ltd.

+ [9]

Inactive Organization

Amgen Research (Munich) GmbH

License Organization

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (03 Dec 2014),

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea), Orphan Drug (United Kingdom), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 112821

Source: *****

The main objective of this trial is to demonstrate that subcutaneous (SC) blinatumomab in conjunction with chemotherapy (Arm B) is non-inferior to continuous intravenous infusion (cIV) blinatumomab in conjunction with chemotherapy (Arm A) in overall survival (OS) in newly diagnosed participants with Philadelphia chromosome (Ph) negative B-cell precursor acute lymphoblastic leukemia (B-ALL) who are in complete remission (CR) or CR with incomplete peripheral count recovery (CRi) after induction.

Start Date30 Jun 2028

Sponsor / Collaborator

Amgen, Inc.

NCT07178912

/ Not yet recruitingPhase 2IIT

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.

Start Date27 Jan 2027

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+2]

NCT07301424

/ Not yet recruitingPhase 2IIT

Phase II Study of Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL Positive B-Cell Acute Lymphoblastic Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive blood cancer; about 30% of B-ALL cases in adults have a mutation called BCR-ABL that drives the disease.
Blinatumomab is an antibody drug that targets B-ALL cells and helps the immune system to kill them. It is usually given intravenously, but a newer formulation can be given under the skin. Ponatinib is a drug, taken by mouth, that targets and kills leukemia cells that have the BCR-ABL mutation.
The goal of this clinical trial is to test the effectiveness of treating patients with BCR-ABL positive B-ALL with blinatumomab given subcutaneously (under the skin) combined with ponatinib tablets. The study will also evaluate what side effects occur using this combination.
Participants will first receive ponatinib tablets for 70 days, along with prednisone for the first month. This will be followed by blinatumomab injections 3 times per week for 4 weeks, repeated for 5 treatment cycles, along with ponatinib. Participants will then continue ponatinib tablets alone for 5 years from the start of treatment.
During treatment, participants will undergo regular blood and bone marrow tests to see how well the treatment is working, and to check for side effects. The effect of this treatments on their quality of life will also be evaluated.

Start Date02 Jan 2027

Sponsor / Collaborator

University of Alberta

[+1]

100 Clinical Results associated with Blinatumomab

Login to view more data

100 Translational Medicine associated with Blinatumomab

Login to view more data

100 Patents (Medical) associated with Blinatumomab

Login to view more data

1,141

Literatures (Medical) associated with Blinatumomab

31 Dec 2026·Hematology

Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature review

Review

Author: Boyko, Diana ; Eichinger, Christian Stefan ; Hodgkinson, Sarah ; Meza, Maria Virginia ; Zaman, Faraz

OBJECTIVES:

Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL) is the most common ALL in adults. Overall survival (OS) with frontline chemotherapy remains poor. Blinatumomab is currently the only targeted agent approved for frontline treatment.

METHODS:

We systematically reviewed 96 studies (43 interventional, 53 observational) between 2012-2026 evaluating frontline pharmacologic therapy in adults with Ph- B-ALL.

RESULTS:

Across chemotherapy studies, nearly half of patients relapsed within 3 years, and only 49%-69% survived beyond 3 years. Blinatumomab demonstrated robust and consistent efficacy in first complete response (CR1), supported by 2 randomized controlled trials (RCT) and 16 single-arm trials (SAT). In one RCT, blinatumomab reduced the risk of death by 59% versus chemotherapy alone (HR 0.41) when added to frontline consolidation in minimal residual disease (MRD) negative patients. Median OS reached 41.2 months in a SAT where blinatumomab monotherapy was administered to patients in MRD-positive CR1. SATs showed consistent efficacy outcomes regardless of age, MRD status, or chemotherapy backbone.

DISCUSSION:

Additional targeted therapies still under investigation have shown mixed results.

CONCLUSION:

Frontline inotuzumab (±blinatumomab) plus chemotherapy showed promise in older populations, while the efficacy benefit of rituximab was inconclusive. No new safety signals were identified in the frontline setting for targeted therapies.

01 Dec 2026·CURRENT TREATMENT OPTIONS IN ONCOLOGY

The Use of Targeted Therapy in Pediatric Acute Lymphoblastic Leukemia: Exploring Novel Approaches and Emerging Therapies

Review

Author: Krieger, Marissa ; Byrwa, David J ; Kelly, Kara M ; Niswander, Lisa M

Opinion Statement:

With modern risk stratification of multi-agent cytotoxic chemotherapy protocols, we now cure the majority of patients with pediatric acute lymphoblastic leukemia (ALL). However, patients with high-risk features or relapsed disease continue to have suboptimal outcomes. Conventional chemotherapy agents may increase long term organ toxicities even in more favorable patients. Improved understanding of the molecular characteristics of pediatric ALL has led to the preclinical and clinical development of more targeted and less systemically toxic therapeutic options for patients with ALL. Agents such as blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and several others have revolutionized the treatment of relapsed or refractory ALL by either directing therapies locally to leukemic cells or by targeting specific leukemogenic pathways. Here we present current evidence for efficacy and toxicity profiles for these targeted therapies in pediatric patients with ALL. Many of these strategies have been more comprehensively studied in the adult population and we will highlight ongoing and needed clinical trials in pediatrics. We need to overcome our historically delayed approach to introducing new therapeutic options in pediatrics, as adults often benefit from innovations for years before they are evaluated in children. More proactively incorporating these emerging treatments into frontline therapy for the most vulnerable, high-risk pediatric ALL populations could meaningfully reshape our treatment paradigm. Earlier collaboration for development of clinical trials across pediatric and adult ALL may facilitate more rapid access to promising agents. We anticipate that successful upfront integration of more targeted approaches will improve response rates, reduce reliance on highly toxic chemotherapies and ultimately increase the likelihood of duration of remission. We expect the next generation of clinical trials will credential more targeted therapies for use in frontline therapy with the goal of improved outcomes with minimized toxicity for all patients with pediatric ALL, not just those with more favorable disease characteristics.

01 Oct 2026·INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Blinatumomab-induced catastrophic immune effector cell-associated neurotoxicity with diffuse cerebral edema in a patient with ALL: Case report

Article

Author: Lin, Rufeng ; Fang, Yongjun ; Guo, Xuemei ; Wei, Yuting

BACKGROUND:

Blinatumomab, a bispecific T-cell engager that targets CD19, has emerged as a significant therapeutic option for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). While immune effector cell-associated neurotoxicity syndrome (ICANS) is a recognized complication, most neurological adverse events are mild to moderate and generally reversible. Catastrophic and fatal neurotoxicity, however, remains exceedingly rare, particularly among pediatric patients.

CASE PRESENTATION:

We present a case involving a 13-year-old boy diagnosed with MLL-AF4-positive precursor B-ALL who experienced catastrophic neurotoxicity during blinatumomab therapy. Following the achievement of molecular remission and successful tolerance of the first treatment cycle without neurological complications, the patient developed an abrupt-onset fever on day 13 of the second cycle. Despite the immediate discontinuation of blinatumomab and the administration of dexamethasone, his condition rapidly deteriorated, leading to confusion, refractory seizures, and coma within hours. Cranial computed tomography revealed diffuse cerebral edema with suspected subarachnoid hemorrhage and impending brain herniation. Intensive supportive management, which included osmotic therapy, antiepileptic treatment, mechanical ventilation, and vasopressor support, failed to reverse the neurological decline. Ultimately, the patient developed irreversible loss of brainstem reflexes and deep coma.

CONCLUSION:

This case underscores a previously unrecognized and severe pattern of delayed-onset, fatal neurotoxicity associated with blinatumomab, which can occur beyond the conventional early treatment window and despite prior tolerance to the drug. Clinicians must remain vigilant for neurological symptoms linked to fever throughout all treatment phases. Further research is urgently required to elucidate risk factors, identify predictive biomarkers, and refine monitoring strategies to avert catastrophic central nervous system injury in pediatric patients undergoing T-cell-engaging immunotherapy.

213

News (Medical) associated with Blinatumomab

02 Oct 2026

·www.biospace.com

Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

iStock, Veronika Oliinyk Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release. Novartis is putting up to $7.8 billion on the line to work with Suzhou, China-based Abogen Biosciences on an mRNA-based approach that could mitigate a key safety concern of T cell engagers. The agreement, announced early on Friday , will involve an upfront payment of $575 million, plus up to around $7.2 billion in potential development, regulatory and commercial milestones. Abogen could also receive royalties on any future sales. The centerpiece of the deal is ABO2203, an mRNA drug candidate designed to deplete disease-causing B cells by giving the patient’s body the genetic code to produce a potentially therapeutic CD3xCD19 T cell engager. This in vivo approach could lower the risk of cytokine release syndrome (CRS), a common and often severe safety issue with T cell engagers, Abogen claimed in a separate press release in April. Indeed, many FDA-approved T cell engagers carry boxed warnings for CRS. These include Roche’s Columvi , J&J’s Tecvayli and Amgen’s Blincyto . ABO2203 has the “potential to transform the treatment landscape for patients with autoimmune diseases,” the companies announced on Friday, though the partners did not explicitly say they would focus their development efforts in this space. A spokesperson for Novartis declined in an email to disclose specific target indications for the deal. First-in-human data for ABO2203 presented in April showed “exceptional” safety among nine patients with relapsed or refractory B cell non-Hodgkin lymphoma, Abogen claimed at the time. Specifically, the Chinese biotech reported no cases of CRS, dose-limiting toxicities or neurological complications typically linked to immunotherapies. Abogen also touted dose-dependent objective response rates, reaching 100% at the highest dose level. Aside from ABO2203, Novartis will also have the exclusive option to license a certain number of therapies developed through Abogen’s proprietary platform. The biotech takes an AI-centric approach to mRNA design, drug formulation and manufacturing, according to the Friday release. “Novartis was attracted to Abogen because of its differentiated proprietary RNA platform and pioneering work in mRNA-encoded T-cell engagers and other RNA-encoded therapeutic modalities,” the spokesperson said. Novartis has taken several trips to China this year. Just last month, the pharma licensed a radioligand asset from Suzhou’s BoomRay Pharmaceuticals for up to $900 million—a deal that could further entrench Novartis’ leadership position in the radiopharma space. And in January, the pharma fronted $150 million to partner with Shanghai- and Maryland-based SciNeuro Pharmaceuticals on an anti-amyloid therapy for Alzheimer’s disease. That deal involved up to $1.5 billion in milestones. During the pharma’s Q2 call in July, CEO Vas Narasimhan said that Novartis is “geography-agnostic” when it comes to dealmaking, adding, “Our strategy is to just go wherever the leading science is in a given therapeutic area or in a given technology area.” The Abogen deal also comes amid a series of setbacks for Novartis , including three deaths linked to its CAR T therapy rapcabtagene autoleucel. As a result, the pharma suspended several studies of the asset. Earnings Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table. July 21, 2026 · 2 min read · Tristan Manalac Read more Clinical research Novartis drags peers down with triple asset stumble Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market. September 11, 2026 · 1 min read · Annalee Armstrong Read more

mRNAImmunotherapyVaccineLicense out/insiRNA

25 Aug 2026

·allsci.com

Antengene preps UCB-partnered CD19 bispecific TCE for first-in-human autoimmune testing in Oz

Australia has cleared ATG-201, Antengene Corporation Limited's (HKEX: 6996.HK) CD19 × CD3 bispecific T-cell engager (TCE), to enter first-in-human testing, with the country's Human Research Ethics Committee (HREC) approving the Phase I ATTRACT study and the Therapeutic Goods Administration (TGA) completing its Clinical Trial Notification process. The approval follows China's NMPA IND clearance in June 2026, opening a two-jurisdiction first-in-human program for the molecule. ATG-201 is built on Antengene's proprietary AnTenGager platform, which uses a "2+1" format — two CD19-binding arms and one CD3-binding arm — combined with steric hindrance masking technology that restricts T-cell activation to the presence of CD19-expressing target cells. The design is intended to deplete pathogenic B cells while reducing cytokine release syndrome (CRS), a known toxicity that has constrained earlier CD19/CD3 bispecific approaches. The ATTRACT study is a dose-escalation and dose-expansion Phase I trial evaluating ATG-201 monotherapy in adult patients with B cell-related autoimmune diseases. Primary endpoints are safety, tolerability, and determination of the recommended Phase II dose (RP2D); secondary endpoints include pharmacokinetic and pharmacodynamic profiling, immunogenicity, and preliminary efficacy. Antengene will conduct the first-in-human studies in both China and Australia before transferring further clinical development to UCB, which holds worldwide exclusive rights to develop, manufacture, and commercialize ATG-201 under a deal signed in March 2026. The UCB agreement provided Antengene with USD 60 million upfront — confirmed received in July 2026 — plus up to USD 20 million in near-term milestones and eligibility for more than USD 1.1 billion in success-based payments and tiered royalties. Preclinical data presented at ACR 2025 showed that ATG-201 achieved complete and sustained B cell depletion in humanized mouse models and demonstrated a favorable safety profile in non-human primates at doses of 1–6 mg/kg, with only mild, transient cytokine elevation. Cryo-electron microscopy confirmed that the CD3 binding site remains sterically masked in the absence of CD19 cross-linking, supporting the conditional activation mechanism. No human data exist yet. CAR-T programs from Kyverna Therapeutics, AstraZeneca, Merck, and others have generated clinical proof-of-concept, while Amgen's blinatumomab — the first-in-class CD19/CD3 bispecific immunotherapy approved for B-cell acute lymphoblastic leukemia — is also under investigation in autoimmune settings. ATG-201's differentiated claim rests on the steric masking mechanism reducing CRS relative to first-generation TCEs, a hypothesis that the ATTRACT study will now begin to test in patients. Spot something wrong? Report an issue with this article

Phase 1INDImmunotherapyLicense out/inPhase 2

07 Aug 2026

·www.pharmaceutical-technology.com

Context drops bispecific T-cell engager on cost-cutting initiative

Context will now focus on its two other pipeline bispecific TCEs, CTIM-76 and CT-202. Credit: ako photography / Shutterstock.com. Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the company looks to cut costs amid a dwindling cash runway. In a Q2 earnings call, Context announced it would be discontinuing CT-95, a mesothelin (MSLN) and CD3-targeting TCE, to home in on its development efforts for the two other assets in its pipeline. Context largely made this decision due to the data generated on CT-95 to date, which did not meet the company’s internal bar for advancement. In a research note, William Blair analyst Matt Phipps noted that, though positive initial data for CT-95 “could have driven significant upside” to Context’s share price, the financial services firm had always taken the stance that MSLN was a high-risk target for TCEs, due to its expression in healthy lung tissues. Context originally acquired CT-95 from Link Immunotherapeutics for $3.75m in 2024, which had progressed the asset to the Phase I-ready stage. Once the drug was in Context’s hands, the biotech began an early-stage study (NCT06756035) looking into its role in treating advanced cancers associated with mesothelin expression, with the Phase Ia dose escalation portion of the study focusing on CT-95 in various forms of gynaecological, lung, gastric and colorectal cancers. The biotech originally planned to share an interim data readout for this study in September. Reallocating focus Context drops CT-95’s clinical development programme as the company looks to reallocate its dwindling capital reserves to higher-priority areas – instead opting to focus on the development of its other two bispecific TCE assets. One of these is Claudin 6 (CLDN6) and CD3-targeting therapy, CTIM-76, which Context is currently evaluating in a Phase Ia trial in platinum-resistant ovarian cancer, with the initial safety, tolerability and efficacy data expected in the second quarter of 2027. The Phase Ib dose expansion trial is set to initiate in Q1 2027. Context originally secured the rights to CTIM-76 through a research collaboration and licensing agreement with Integral Molecular. Another is CT-202, which targets Nectin-4 and CD3. Context will soon enter the drug into a Phase I trial evaluating its potential in urothelial, colorectal and triple-negative breast cancer (TNBC). The company expects to dose the first patient in this trial during the third quarter of 2026. Context plans to debut initial safety data from the Phase Ia in the second quarter of 2027, and hopes to begin the Phase Ib dose expansion portion of the study in Q1 2027. BiTE market picks up GlobalData forecasts that the BiTE market will experience growth in the coming years, reaching over $20bn by 2030. Analysts predict that Johnson & Johnson will lead the commercial space, driven by Tecvayli (teclistamab) and Talvey (talquetamab), while R&D expands from late-line blood cancers into solid tumours and earlier treatment lines. Amgen’s Blincyto, which received FDA approval for B-cell lymphoblastic leukaemia in 2014, was the highest-selling BiTE in 2023, with $897m in sales. In 2023, BiTEs collectively generated $1.45bn in global sales. Analysts predict that Roche will be the runner-up company sales-wise in the 2030 BiTE market, as they say three of its products will $2.9bn. The Swiss pharma giant’s top product, Columnvi, is forecast to generate $1.7bn, becoming the third top-selling BiTE behind Tecvayli and Talvey. GlobalData is the parent company of Pharmaceutical Technology .

Phase 1Drug ApprovalLicense out/inAcquisitionImmunotherapy

100 Deals associated with Blinatumomab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09325	Blinatumomab	L01XC19	DB09052

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Recurrent B Acute Lymphoblastic Leukemia	Japan	Amgen, Inc.	21 Sep 2018
Refractory B Acute Lymphoblastic Leukemia	Japan	Amgen, Inc.	21 Sep 2018
Acute Lymphoblastic Leukemia	Canada	Amgen Canada, Inc.	22 Dec 2015
CD19-positive B-cell Precursor acute lymphoblastic leukemia	European Union	Amgen Europe BV	23 Nov 2015
CD19-positive B-cell Precursor acute lymphoblastic leukemia	Iceland	Amgen Europe BV	23 Nov 2015
CD19-positive B-cell Precursor acute lymphoblastic leukemia	Liechtenstein	Amgen Europe BV	23 Nov 2015
CD19-positive B-cell Precursor acute lymphoblastic leukemia	Norway	Amgen Europe BV	23 Nov 2015
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	European Union	Amgen Europe BV	23 Nov 2015
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Iceland	Amgen Europe BV	23 Nov 2015
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Liechtenstein	Amgen Europe BV	23 Nov 2015
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Norway	Amgen Europe BV	23 Nov 2015
Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	Australia	Amgen Australia Pty Ltd.	09 Nov 2015
Philadelphia positive acute lymphocytic leukaemia	Australia	Amgen Australia Pty Ltd.	09 Nov 2015
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	United States	Amgen, Inc.	03 Dec 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
BCR-ABL1 positive Acute Lymphoblastic Leukemia	Phase 3	United States	National Cancer Institute	25 Jan 2021
BCR-ABL1 positive Acute Lymphoblastic Leukemia	Phase 3	Israel	National Cancer Institute	25 Jan 2021
Down Syndrome	Phase 3	United States	National Cancer Institute	03 Jul 2019
Down Syndrome	Phase 3	Australia	National Cancer Institute	03 Jul 2019
Down Syndrome	Phase 3	Canada	National Cancer Institute	03 Jul 2019
Down Syndrome	Phase 3	New Zealand	National Cancer Institute	03 Jul 2019
Advanced Marginal Zone Lymphoma	Phase 3	United States	Amgen, Inc.	23 Jan 2017
Advanced Marginal Zone Lymphoma	Phase 3	Australia	Amgen, Inc.	23 Jan 2017
Advanced Marginal Zone Lymphoma	Phase 3	Belgium	Amgen, Inc.	23 Jan 2017
Advanced Marginal Zone Lymphoma	Phase 3	Canada	Amgen, Inc.	23 Jan 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02458014 (CTgov)	Phase 2	Residual Neoplasm \| Refractory B Acute Lymphoblastic Leukemia	37	blinatumomab (Treatment (Blinatumomab))	vemgqsgzdk(szaxqvpiwg) = zbximzkdwl hewjtnndig (eogwqkfocc, htlvbxtofv - bcandxadxt) View more	-	25 Sep 2026
NCT02458014 (CTgov)	Phase 2		37	TKI+blinatumomab (Treatment (Blinatumomab + TKI))	vemgqsgzdk(szaxqvpiwg) = yfzfpsjdrm hewjtnndig (eogwqkfocc, dspkxzeffh - sqxxigjjvn) View more	-	25 Sep 2026
EULAR2026	Not Applicable	Rheumatoid Arthritis	15	Blinatumomab (Multidrug-resistant RA)	nhlrvmzmzi(qpvzxnpcac) = rimhqvakud caibxoxlzq (gnelcnmbfy ) View more	Positive	11 Jun 2026
NCT03263572 (ASCO2026)	Phase 2	Philadelphia positive acute lymphocytic leukaemia First line BCR::ABL1 p190 \| BCR::ABL1 p210 \| IKZF1+	88	Blinatumomab + Ponatinib	ndeedotlze(xhywggyoic) = vueshdtovc rjgnqwanvk (fcgoeyygst ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Acute Lymphoblastic Leukemia \| Small Cell Carcinoma \| B-Cell Lymphoma ... View more	3,642	bispecific T-cell engager therapy	rlstqohdqv(mwkulzgjuk) = sgbjljbhrr ylocsjdoza (szwkmplido ) View more	Positive	29 May 2026
NCT06649006 (CTgov)	Phase 1	Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	6	Blinatumomab (Evaluable Participants: Blinatumomab)	zycmlgyrzd = gxmnlphkji nfwoazjopv (xglualqyad, uqlkjwlhxh - dwmltidpbv) View more	-	13 May 2026
NCT06649006 (CTgov)	Phase 1		6	Blinatumomab (Non-evaluable Participants: Blinatumomab)	zycmlgyrzd = ystxxlqvzv nfwoazjopv (xglualqyad, hbktolmbov - uoxuivfifq) View more	-	13 May 2026
EHA2026	Phase 1/2	Philadelphia positive acute lymphocytic leukaemia	10	Blinatumomab + Asciminib	yrctmmrmyx(jbeohczezr) = No grade 3 or higher related adverse events were observed qasvnrdrno (nxazzrrcok ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	107	hyperCVAD + dasatinib	mzsfnvhqru(dmmxwttgou) = qgwtasddvp wwsromhmew (bdfthcdltt ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	107	hyperCVAD + imatinib	mzsfnvhqru(dmmxwttgou) = vxrepxahag wwsromhmew (bdfthcdltt ) View more	Positive	12 May 2026
NCT07222579 (EHA2026)	Phase 2	Mixed phenotype acute leukemia CD19 positive	75	Subcutaneous Blinatumomab + Dasatinib (Newly Diagnosed CD19+ MPAL)	dujkmzguty(algaznvupt) = hzjwmygbeo gkhnalczts (fedpktbqef ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Acute Lymphoblastic Leukemia	61	Blinatumomab (B-lineager ALL)	qvqsdklysp(pcimsljyol) = siuijuzjit mogijntpsx (tooucsmpvg ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Acute Lymphoblastic Leukemia	61	Standard Chemotherapy (B-lineager ALL + Caregivers)	qvqsdklysp(pcimsljyol) = popvxwdcwk mogijntpsx (tooucsmpvg ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Adult Acute Lymphocytic Leukemia Consolidation	6	Blinatumomab	hjsnldlqcz(lrqpwbyrzo) = Non-CRS adverse events included grade 2 transaminitis (n=2), one deep vein thrombosis, and two infectious complications (one upper respiratory tract infection due to respiratory syncytial virus and one catheter-related Pseudomonas aeruginosa infection). The catheter-related infection resolved after catheter removal and antibiotic therapy, requiring a temporary 3-day interruption of blinatumomab but no hospitalization. Infusion device-related issues prompted 8 additional outpatient visits, due to pump occlusion alarms, blood reflux, or accidental port-a-cath disconnection. All were managed without hospital admission. No ICU admissions or treatment‐related deaths occurred. otsyrqubbw (atgekkilzg ) View more	Positive	12 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Blinatumomab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation